First Western Trust Bank Sells 4,728 Shares of Danaher Co. (NYSE:DHR)

First Western Trust Bank trimmed its position in Danaher Co. (NYSE:DHR) by 14.6% in the 2nd quarter, Holdings Channel.com reports. The fund owned 27,610 shares of the conglomerate’s stock after selling 4,728 shares during the quarter. Danaher makes up approximately 0.3% of First Western Trust Bank’s portfolio, making the stock its 24th biggest position. First Western Trust Bank’s holdings in Danaher were worth $6,898,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the business. Cary Street Partners Investment Advisory LLC grew its stake in Danaher by 20.2% during the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after buying an additional 1,533 shares during the last quarter. Caden Capital Partners LP grew its stake in shares of Danaher by 12.4% during the fourth quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after acquiring an additional 15,313 shares during the last quarter. JARISLOWSKY FRASER Ltd increased its holdings in shares of Danaher by 10.8% during the fourth quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after acquiring an additional 55,908 shares in the last quarter. HighPoint Advisor Group LLC purchased a new position in shares of Danaher in the 4th quarter valued at approximately $2,614,000. Finally, Norden Group LLC acquired a new stake in Danaher in the 1st quarter worth approximately $4,151,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Danaher

In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the sale, the director now owns 41,149 shares in the company, valued at $11,501,145.50. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock valued at $11,042,433 in the last three months. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Up 0.1 %

DHR opened at $264.80 on Friday. The company has a fifty day moving average of $260.98 and a two-hundred day moving average of $255.61. The stock has a market capitalization of $196.13 billion, a price-to-earnings ratio of 44.88, a PEG ratio of 4.43 and a beta of 0.83. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.15. The firm had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a return on equity of 11.06% and a net margin of 16.94%. Danaher’s revenue for the quarter was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.05 EPS. On average, research analysts expect that Danaher Co. will post 7.59 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on DHR. TD Cowen upped their price target on shares of Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Evercore ISI reduced their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Royal Bank of Canada boosted their price target on Danaher from $297.00 to $300.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Jefferies Financial Group started coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective for the company. Finally, Bank of America upped their target price on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, Danaher has a consensus rating of “Moderate Buy” and an average price target of $278.94.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.